Antengene Provides an Update on Its Latest Developments
PR Newswire Asia
· Announces two new in-house discovered assets - ATG-031, a potential first-in-class anti-CD24 monoclonal antibody, and ATG-027, a..
NFE2L2
News and Video Search Results
News coverage
-
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
GlobeNewswire
-
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
GlobeNewswire
-
Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations
PR Newswire Asia
-
Antengene Announces Financial Results for Full Year 2020
PR Newswire Asia
0 shares
1 views
You might like
NFE2L2 media coverage
Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021
SHANGHAI and GAITHERSBURG, Md., March 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a..
PR Newswire Asia
Genetron Health to Highlight Data from 18 Studies at ESMO 2020
Genetron Health to present data at ESMO 2020 relating to precision oncology diagnostic development initiatives across lung,..
GlobeNewswire